PainReform LTD   Report issue

For profit Phase 3
Founded: Herzliya Israel (2007)
Status: Left NME R&D (2021)

Organization Overview

First Clinical Trial
2010
NCT00883194
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

PainReform LTD

Active Ingredients

Drugs in Phase 3 Trials (1)

ropivacaine (naropin) (4 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Pain, Postoperative (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 1